Artal Participations S.a r.l. - 30 Apr 2026 Form 4 Insider Report for LEXICON PHARMACEUTICALS, INC. (LXRX)

Reporting relationship: Director, 10%+ Owner
Issuer ticker: LXRX
Reported as of: 30 Apr 2026
Net transaction value: $0
SEC form: 4
Accepted by SEC: 08 May 2026, 21:45:20 UTC
Prior SEC filing: 19 Feb 2026
Next SEC filing: 17 Jun 2026
Source filing: View source filing
Reporting owner signature: See Exhibit 99.1

Key filing fact

Artal Participations S.a r.l. filed Form 4 for LEXICON PHARMACEUTICALS, INC. (LXRX) on 08 May 2026.

Key facts

This page summarizes Artal Participations S.a r.l.'s Form 4 filing for LEXICON PHARMACEUTICALS, INC. (LXRX).
3 reported transactions and 14 derivative rows are listed below.
Accepted by SEC: 08 May 2026, 21:45.

Change

Previous filing in this sequence was filed on 19 Feb 2026.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (7)

CIK 0002048403 Primary reporting owner

Artal Participations S.a r.l.

Relationship: Director, 10%+ Owner
Address: VALLEY PARK 44, RUE DE LA VALLEE, LUXEMBOURG, LUXEMBOURG
Signature: See Exhibit 99.1
Signature date: 08 May 2026

CIK 0001218180

Artal International S.C.A.

Relationship: Director, 10%+ Owner
Address: VALLEY PARK, 44, RUE DE LA VALLEE, LUXEMBOURG, LUXEMBOURG
Signature: See Exhibit 99.1
Signature date: 08 May 2026

CIK 0001522131

Artal International Management S.A.

Relationship: Director, 10%+ Owner
Address: VALLEY PARK, 44, RUE DE LA VALLEE, LUXEMBOURG, LUXEMBOURG
Signature: See Exhibit 99.1
Signature date: 08 May 2026

CIK 0001053906

Artal Group S.A.

Relationship: Director, 10%+ Owner
Address: VALLEY PARK, 44, RUE DE LA VALLEE, LUXEMBOURG, LUXEMBOURG
Signature: See Exhibit 99.1
Signature date: 08 May 2026

CIK 0001283968

Westend S.A.

Relationship: Director, 10%+ Owner
Address: VALLEY PARK, 44, RUE DE LA VALLEE, LUXEMBOURG, LUXEMBOURG
Signature: See Exhibit 99.1
Signature date: 08 May 2026

CIK 0001460840

Stichting Administratiekantoor Westend

Relationship: Director, 10%+ Owner
Address: H.J.E. WENCKEBACHWEG 252, AMSTERDAM, NETHERLANDS
Signature: See Exhibit 99.1
Signature date: 08 May 2026

CIK 0001841311

Wittouck Amaury

Relationship: Director, 10%+ Owner
Address: VALLEY PARK, 44, RUE DE LA VALLEE, LUXEMBOURG, LUXEMBOURG
Signature: See Exhibit 99.1
Signature date: 08 May 2026

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

LXRX transaction

Common Stock

Options Exercise

Transaction value
Shares: +20,421,735
Change %: +13%
Price: $0.000000^*
Shares after: 175,156,062
Date: 30 Apr 2026
Ownership: See Footnotes
Footnotes: F1, F2, F3, F4

LXRX transaction

Common Stock

Options Exercise

Transaction value
Shares: +20,421,735
Change %: +13%
Price: $0.000000^*
Shares after: 175,156,062
Date: 30 Apr 2026
Ownership: See Footnotes
Footnotes: F1, F2, F3, F4

LXRX transaction

Common Stock

Options Exercise

Transaction value
Shares: +20,421,735
Change %: +13%
Price: $0.000000^*
Shares after: 175,156,062
Date: 30 Apr 2026
Ownership: See Footnotes
Footnotes: F1, F2, F3, F4

LXRX transaction

Common Stock

Options Exercise

Transaction value
Shares: +20,421,735
Change %: +13%
Price: $0.000000^*
Shares after: 175,156,062
Date: 30 Apr 2026
Ownership: See Footnotes
Footnotes: F1, F2, F3, F4

LXRX transaction

Common Stock

Options Exercise

Transaction value
Shares: +20,421,735
Change %: +13%
Price: $0.000000^*
Shares after: 175,156,062
Date: 30 Apr 2026
Ownership: See Footnotes
Footnotes: F1, F2, F3, F4

LXRX transaction

Common Stock

Options Exercise

Transaction value
Shares: +20,421,735
Change %: +13%
Price: $0.000000^*
Shares after: 175,156,062
Date: 30 Apr 2026
Ownership: See Footnotes
Footnotes: F1, F2, F3, F4

LXRX transaction

Common Stock

Options Exercise

Transaction value
Shares: +20,421,735
Change %: +13%
Price: $0.000000^*
Shares after: 175,156,062
Date: 30 Apr 2026
Ownership: See Footnotes
Footnotes: F1, F2, F3, F4

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

LXRX transaction Derivative

Series B Convertible Preferred Stock

Award

Transaction value
Shares: +408,435
Change %
Price
Shares after: 408,435
Date: 30 Apr 2026
Ownership: See Footnotes
Underlying class: Common Stock
Underlying amount: 20,421,735
Exercise price
Footnotes: F1, F2, F3, F4

LXRX transaction Derivative

Series B Convertible Preferred Stock

Award

Transaction value
Shares: +408,435
Change %
Price
Shares after: 408,435
Date: 30 Apr 2026
Ownership: See Footnotes
Underlying class: Common Stock
Underlying amount: 20,421,735
Exercise price
Footnotes: F1, F2, F3, F4

LXRX transaction Derivative

Series B Convertible Preferred Stock

Award

Transaction value
Shares: +408,435
Change %
Price
Shares after: 408,435
Date: 30 Apr 2026
Ownership: See Footnotes
Underlying class: Common Stock
Underlying amount: 20,421,735
Exercise price
Footnotes: F1, F2, F3, F4

LXRX transaction Derivative

Series B Convertible Preferred Stock

Award

Transaction value
Shares: +408,435
Change %
Price
Shares after: 408,435
Date: 30 Apr 2026
Ownership: See Footnotes
Underlying class: Common Stock
Underlying amount: 20,421,735
Exercise price
Footnotes: F1, F2, F3, F4

LXRX transaction Derivative

Series B Convertible Preferred Stock

Award

Transaction value
Shares: +408,435
Change %
Price
Shares after: 408,435
Date: 30 Apr 2026
Ownership: See Footnotes
Underlying class: Common Stock
Underlying amount: 20,421,735
Exercise price
Footnotes: F1, F2, F3, F4

LXRX transaction Derivative

Series B Convertible Preferred Stock

Award

Transaction value
Shares: +408,435
Change %
Price
Shares after: 408,435
Date: 30 Apr 2026
Ownership: See Footnotes
Underlying class: Common Stock
Underlying amount: 20,421,735
Exercise price
Footnotes: F1, F2, F3, F4

LXRX transaction Derivative

Series B Convertible Preferred Stock

Award

Transaction value
Shares: +408,435
Change %
Price
Shares after: 408,435
Date: 30 Apr 2026
Ownership: See Footnotes
Underlying class: Common Stock
Underlying amount: 20,421,735
Exercise price
Footnotes: F1, F2, F3, F4

LXRX transaction Derivative

Series B Convertible Preferred Stock

Options Exercise

Transaction value
Shares: -408,435
Change %: -100%
Price: $0.000000^*
Shares after: 0
Date: 30 Apr 2026
Ownership: See Footnotes
Underlying class: Common Stock
Underlying amount: 20,421,735
Exercise price
Footnotes: F1, F2, F3, F4

LXRX transaction Derivative

Series B Convertible Preferred Stock

Options Exercise

Transaction value
Shares: -408,435
Change %: -100%
Price: $0.000000^*
Shares after: 0
Date: 30 Apr 2026
Ownership: See Footnotes
Underlying class: Common Stock
Underlying amount: 20,421,735
Exercise price
Footnotes: F1, F2, F3, F4

LXRX transaction Derivative

Series B Convertible Preferred Stock

Options Exercise

Transaction value
Shares: -408,435
Change %: -100%
Price: $0.000000^*
Shares after: 0
Date: 30 Apr 2026
Ownership: See Footnotes
Underlying class: Common Stock
Underlying amount: 20,421,735
Exercise price
Footnotes: F1, F2, F3, F4

LXRX transaction Derivative

Series B Convertible Preferred Stock

Options Exercise

Transaction value
Shares: -408,435
Change %: -100%
Price: $0.000000^*
Shares after: 0
Date: 30 Apr 2026
Ownership: See Footnotes
Underlying class: Common Stock
Underlying amount: 20,421,735
Exercise price
Footnotes: F1, F2, F3, F4

LXRX transaction Derivative

Series B Convertible Preferred Stock

Options Exercise

Transaction value
Shares: -408,435
Change %: -100%
Price: $0.000000^*
Shares after: 0
Date: 30 Apr 2026
Ownership: See Footnotes
Underlying class: Common Stock
Underlying amount: 20,421,735
Exercise price
Footnotes: F1, F2, F3, F4

LXRX transaction Derivative

Series B Convertible Preferred Stock

Options Exercise

Transaction value
Shares: -408,435
Change %: -100%
Price: $0.000000^*
Shares after: 0
Date: 30 Apr 2026
Ownership: See Footnotes
Underlying class: Common Stock
Underlying amount: 20,421,735
Exercise price
Footnotes: F1, F2, F3, F4

LXRX transaction Derivative

Series B Convertible Preferred Stock

Options Exercise

Transaction value
Shares: -408,435
Change %: -100%
Price: $0.000000^*
Shares after: 0
Date: 30 Apr 2026
Ownership: See Footnotes
Underlying class: Common Stock
Underlying amount: 20,421,735
Exercise price
Footnotes: F1, F2, F3, F4

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 4 footnotes

Footnote F1

Pursuant to the terms of a Preferred Stock Purchase Agreement, dated as of January 29, 2026, Artal Participations S.a r.l. acquired an aggregate of 408,434.70 shares of Series B convertible preferred stock, $0.01 par value per share (the "Preferred Stock") of the Issuer at a price of $65.00 per share. Each share of Preferred Stock would automatically convert into 50 shares of the Issuer's common stock, par value $0.001 per share (the "Common Stock") upon receipt of shareholder approval and the satisfaction of certain other conditions (the "Conditions"); however, absent the satisfaction of such conditions, the shares were not convertible, and as such, the Preferred Stock was originally reported on Table I. On April 30, 2026, all Conditions were met, and the 408,434.70 shares of Preferred Stock became derivative securities and automatically converted into 20,421,735 shares of Issuer Common Stock.

Footnote F2

These securities are directly held by Artal Participations S.a r.l.

Footnote F3

The sole shareholder of Artal Participations S.a r.l. is Artal International S.C.A. The managing partner of Artal International S.C.A. is Artal International Management S.A. The sole stockholder of Artal International Management S.A. is Artal Group S.A. The parent company of Artal Group S.A. is Westend S.A. The majority stockholder of Westend S.A. is Stichting Administratiekantoor Westend (the "Stichting"). Mr. Amaury Wittouck is the sole member of the board of the Stichting.

Footnote F4

Each of the Reporting Persons (other than to the extent it directly holds securities reported herein) disclaims beneficial ownership of the securities held by the other Reporting Persons, except to the extent of such Reporting Person's pecuniary interest therein, and, pursuant to Rule 16a-1(a)(4) under the Securities Exchange Act of 1934, as amended (the "Exchange Act"), each of the Reporting Persons (other than to the extent it directly holds securities reported herein) states that the inclusion of these securities in this report shall not be deemed an admission of beneficial ownership of all of the reported securities for purposes of Section 16 of the Exchange Act or for any other purpose.

SEC remarks

Invus Public Equities, L.P. directly holds 7,362,368 shares of Common Stock, Invus, L.P. directly owns 35,402,689 shares of Common Stock, Invus US Partners LLC directly owns 5,451,204 shares of Common Stock, Mr. Debbane directly owns 1,906,186 shares of Common Stock, Avicenna Life Sci Master Fund LP directly owns 1,538,462 shares of Common Stock and Artal Participations S.a r.l. directly owns 175,156,062 shares of Common Stock, which securities are reported on separate Form 4 filings. For purposes of Section 16 of the Exchange Act, the Reporting Persons may be deemed to be directors by deputization of the Issuer by virtue of Invus, L.P.'s right to designate certain members of the Issuer's board of directors pursuant to a stockholders' agreement between the Issuer and Invus, L.P.